FLT3突变作为急性髓系白血病诊断与预后生物标志物
本综述从临床实验室视角阐述FLT3突变(ITD与TKD)在急性髓系白血病(AML)诊断、风险分层、治疗规划及可测量残留病(MRD)监测中的作用。文章讨论了等位基因负荷、变异等位基因频率、插入位点、共突变背景及ELN 2022解读对FLT3结果临床意义的影响,并强调FLT3应作为整合性生物标志物而非简单阴阳性结果。
要点
- FLT3-ITD与FLT3-TKD突变与复发风险、缓解持续时间、生存及FLT3抑制剂反应相关。
- FLT3结果解读需结合等位基因负荷、变异等位基因频率、插入位点、结构特征与共突变背景。
- 实验室应关注PCR、片段分析、NGS与ddPCR的方法学性能、突变定量与跨平台标准化。
核心结论
- FLT3应作为整合性临床实验室生物标志物使用,而非简单的突变阳性或阴性结果。
- FLT3的突变亚型、分子背景、治疗设置、检测性能与标准化报告共同决定其诊断、预后、预测及MRD相关价值。
研究设计与样本
- 综述,检索范围未在原文中具体报告。
主要发现
- FLT3-ITD和FLT3-TKD突变与复发风险、缓解持续时间、生存、FLT3抑制剂反应及可测量残留病检测相关。
- 等位基因负荷、变异等位基因频率、插入位点、结构特征、共突变背景、ELN 2022解读及治疗暴露有助于阐明FLT3结果的临床意义。
关键数值与推荐
- 原文提及ELN 2022对FLT3结果的解读,但未给出具体数值或推荐条款。
临床怎么用
- 实验室检测应涵盖PCR、片段分析、下一代测序与微滴数字PCR,并关注检测灵敏度、突变定量、结构注释及跨平台标准化。
- 报告FLT3结果时应整合突变亚型、分子背景、治疗设置与检测性能,而非仅报告突变阳性或阴性。
局限性
- 原文未报告综述的检索范围、纳入标准及证据质量评价方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) is a diverse and complex haematological cancer that cannot be fully characterized, even with the combination of morphology and cytogenetics. As a result, molecular biomarkers have become the focus of diagnosis, risk stratification, therapeutic planning and monitoring of disease. Of these, FLT3 mutations have been identified as being clinically relevant, clinically important, and easily detected during various phases of AML care. This review examines the diagnostic, prognostic, predictive and monitoring role of FLT3 mutations in AML, with a focus on the clinical applications in the laboratory. We review the evidence for FLT3 internal tandem duplication (FLT3-ITD) and FLT3 tyrosine kinase domain (FLT3-TKD) mutations, their association with relapse risk, remission duration, survival, response to FLT3 inhibitors and measurable residual disease testing. The impact of allelic burden, variant allele frequency, insertion site, structural characteristics, co-mutational background, interpretation of FLT3 results in ELN 2022, and treatment exposure help clarify the clinical significance of FLT3 results. A particular focus is placed on laboratory assay implementation, including PCR-based assays, fragment analysis, next-generation sequencing and droplet digital PCR, as well as assay sensitivity, mutation quantification, structural annotation, and inter-platform standardization. FLT3 should be used as an integrated clinical laboratory biomarker and not a simple mutation-positive or mutation-negative result. Its mutation subtype, molecular context, treatment setting, assay performance and standardized reporting determine its diagnostic, prognostic, predictive and MRD-related value. This review offers a clinical laboratory perspective on how to interpret FLT3 mutations as actionable biomarkers in AML.
引用
- Thapa R, Fuloria NK, Bhat AA, et al. FLT3 mutations as diagnostic and prognostic biomarkers in acute myeloid leukemia. Clin Chim Acta. 2026. PMID: 42235731. doi:10.1016/j.cca.2026.121132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。